What is the recommended domperidone dosing for an adult with chronic kidney disease?

Domperidone Dosing in Chronic Kidney Disease

Domperidone undergoes extensive hepatic metabolism with minimal renal excretion (only ~1% unchanged in urine), so dose adjustment based solely on kidney function is generally not required; however, use extreme caution and limit doses to ≤30 mg/day in patients with any degree of renal impairment due to increased risk of sudden cardiac death. 1, 2

Pharmacokinetic Rationale for Dosing

• Domperidone is primarily eliminated through hepatic metabolism (hydroxylation and N-dealkylation), with 66% fecal excretion and only 31% urinary excretion, of which approximately 1% is unchanged drug 1
• The drug is 91-93% protein-bound, which may be altered in advanced CKD due to uremia, potentially increasing free drug concentrations 1
• Hepatic clearance remains the dominant elimination pathway, making traditional renal dose adjustments less critical from a pharmacokinetic standpoint 1

Critical Safety Considerations in CKD

The primary concern with domperidone in CKD is cardiovascular safety, not drug accumulation. 2

• Limit daily doses to ≤30 mg in all patients with CKD, as doses exceeding this threshold are associated with increased sudden cardiac death risk based on observational epidemiological studies 2
• Assess each patient individually for additional cardiac risk factors (QT prolongation, electrolyte abnormalities, concurrent QT-prolonging medications) before initiating therapy 2
• No randomized controlled trials have definitively proven increased sudden cardiac death risk, but regulatory warnings from Health Canada, European Medicines Agency, and FDA are based on two large observational studies showing a dose-related signal 2

Practical Dosing Approach

• Start with the lowest effective dose (typically 10 mg three times daily) rather than standard doses used in patients with normal renal function 2
• Avoid doses exceeding 30 mg/day total in any patient with estimated GFR <60 mL/min/1.73 m² 2
• Monitor for cardiac arrhythmias and QT prolongation with baseline and follow-up ECGs, particularly in patients with eGFR <30 mL/min/1.73 m² 2
• Check and correct electrolyte abnormalities (potassium, magnesium, calcium) before and during therapy, as these are common in CKD and independently increase arrhythmia risk 2

Special Populations

For patients on hemodialysis, no direct evidence exists to guide dosing, but the same conservative approach applies given the drug's hepatic metabolism and cardiovascular safety concerns 2

• Use domperidone only when benefits clearly outweigh risks in end-stage renal disease 2
• Consider alternative prokinetic agents if available and appropriate for the clinical indication 2

Common Pitfalls to Avoid

• Do not assume standard dosing is safe simply because renal excretion is minimal—the cardiovascular risk is dose-dependent regardless of kidney function 2
• Do not overlook drug interactions with CYP3A4 inhibitors (azole antifungals, macrolides), which can increase domperidone levels and further elevate cardiac risk 2
• Do not use domperidone chronically without periodic reassessment of ongoing need and cardiac safety monitoring 2